PTC Therapeutics

United States
South Plainfield, New Jersey, United States, 07080-2449

Company profile

PTC Therapeutics company profile

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Business identity

Contact email
[email protected]
Phone number
+1 908 222 7000
Operating status
Active
Company type
For Profit
Employee range
501-1,000 employees
Revenue range
$500,000+
Founded
1998-01-01, Year

Headquarters

Postal code
07080-2449
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
15
Total equity funding
$1.4B
Last funding
Post IPO Equity / $1B / 2022-10-27
Last equity funding
Post IPO Equity / $1B
Investors
24
Lead investors
7
Founders
2
Articles
612
Exited on
2013-06-20

Founders and investors

Founders

Allan JacobsonStuart Peltz

Lead investors

Bay City CapitalBrookside CapitalCredit SuisseCredit Suisse First BostonDelphi VenturesHBM Healthcare InvestmentsThe Column Group

Investors

Adage Capital ManagementBlackstone CreditLongwood FundNovo HoldingsWellcome Trust